An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2389-2400

  Currie, Craig J ^a   Poole, Chris D ^b   Papo, Natalie L ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^c Medtronic International ^*  (Switzerland)

Author keywords

Clinical trials; Continuous glucose monitoring; Diabetes; Outcome; Review

Indexed keywords

HEMOGLOBIN A1C;

BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; DATA BASE; DIAGNOSTIC ACCURACY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; MONITORING, PHYSIOLOGIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70349330813     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903094452     Document Type: Note

References (59)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
2. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2004;21:657-665 (Pubitemid 38916208)
3. Hirsch IB. Glycemic variability: it's not just about A1C anymore! Diabetes Tech Therapeut 2005;75:780-783
4. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). Available at: http://www.nice.org. uk/Guidance/CG66 [Last accessed 17 November 2008]
5. Deiss D, Kordonouri O, Hartmann R, et al. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Pediatr Diabetes 2007;8:157-162 (Pubitemid 46864297)
6. Abrahamian H, Francesconi M, Loiskandl A, et al. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Tech Therapeut 2004;6:31-37 (Pubitemid 38233743)
7. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653 (Pubitemid 41817713)
8. Selvin E, Coresh J, Golden SH, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005;165:1910-1916 (Pubitemid 41352087)
9. Jenny-Avital ER, Luan FL, Nguyen K, et al. Intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1519-1521
10. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
11. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
12. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
13. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: Eur Heart J 2007;28:88-136
14. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-2633
15. Duckworth WC, McCarren M, Abraira C; VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocr Pract 2006;12(Suppl. 1):85-88 (Pubitemid 44963619)
16. Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J 2004;147:803-807 (Pubitemid 38880985)
17. Slama G. Clinical significance of post-prandial blood glucose excursions in type 1 and type 2 diabetes mellitus. Int J Clin Pract 2000;112(Suppl.):9-12
18. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c-Derived Average Glucose (ADAG) Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478
19. Mastrototaro JJ. The MiniMed continuous glucose monitoring system. Diabetes Tech Therapeut 2000;2(Suppl. 1):S13-8
20. Rebrin K, Steil GM, van Antwerp WP, et al. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol 1999;277(3 Pt 1):E561-71
21. Boyne MS, Silver DM, Kaplan J, et al. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003;52:2790-2794 (Pubitemid 37339709)
22. Metzger M, Leibowitz G, Wainstein J, et al. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002;25:1185-1191 (Pubitemid 41071170)
23. Steil GM, Rebrin K, Mastrototaro J, et al. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Tech Therapeut 2003;5:27-31 (Pubitemid 36506087)
24. Guerci B, Floriot M, Böhme P, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 2003;26:582-589 (Pubitemid 36929311)
25. Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet Med 2003;20:1012-1015 (Pubitemid 41701482)
26. Djakoure-Platonoff C, Radermecker R, Reach G, et al. Accuracy of the continuous glucose sensor. Diabetes Care 2002;25:1185-1191
27. McGowan K, Thomas W, Moran A. Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. Diabetes Care 2002;25:1499-1503 (Pubitemid 41071101)
28. Cheyne E, Kerr D. Making 'sense' of diabetes: using a continuous glucose sensor in clinical practice. Diabetes Metabol Res Rev 2002;18(Suppl. 1):S43-S48
29. Clarke WL. The original Clarke Error Grid Analysis (EGA). Diabetes Tech Therapeut 2005;7:776-779
30. Lagarde WH, Barrows FP, Davenport ML, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial. Pediatr Diabetes 2006;7:159-164 (Pubitemid 43916285)
31. Deiss D, Hartmann R, Schmidt J, et al. Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2006;11:63-67
32. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003;111:933-938 (Pubitemid 36542603)
33. Yates K, Hasnat Milton A, Dear K, et al. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens: a randomized controlled trial. Diabetes Care 2006;29:1512-1517 (Pubitemid 44127573)
34. Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924-932
35. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005;22:749-755 (Pubitemid 40805897)
36. Currie CJ, Morgan CLl, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:523-534
37. Chase HP, Kim LM, Owen SL, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001;107:222-226 (Pubitemid 32121233)
38. Tanenberg R, Bode B, Lane W, et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc 2004;79:1521-1526 (Pubitemid 39578876)
39. Chico A, Vidal-Ríos P, Subirà M, et al. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153-1157 (Pubitemid 36929264)
40. Chetty VT, Almulla A, Odueyungbo A, et al. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: a systematic review. Diab Res Clin Pract 2008;81:79-87
41. Golicki DT, Golicka D, Groele L, et al. Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 2008;51:233-240
42. Reach G. Continuous glucose monitoring and diabetes health outcomes: a critical appraisal. Diabetes Tech Therapeut 2008;10:69-80 (Pubitemid 351230288)
43. Boland E, Monsod T, Delucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858-1862 (Pubitemid 33716491)
44. Schiaffini R, Ciampalini P, Fierabracci A, et al. The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk. Diabetes Metabol Res Rev 2002;18:324-329
45. Amin R, Ross K, Acerini CL, et al. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: using of continuous glucose monitoring system. Diabetes Care 2003;26:662-667 (Pubitemid 36929324)
46. Gandrud LM, Xing DY, Kollman C, et al. The medtronic MiniMed gold continuous glucose monitoring system: an effective means to discover hypo- and hyperglycemia in children under 7 years of age. Diabetes Tech Therapeut 2007;9:307-316 (Pubitemid 47340081)
47. Wiltshire EJ, Newton K, McTavish L. Unrecognised hypoglycaemia in children and adolescents with type 1 diabetes using the continuous glucose monitoring system: prevalence and contributors. J Paediatr Child Health 2006;42:758-763 (Pubitemid 44690820)
48. Yogev Y, Chen R, Ben-Haroush A, et al. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. Obstet Gynecol 2003;101:633-638 (Pubitemid 36390048)
49. Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485-1489 (Pubitemid 36929183)
50. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Tech Therapeut 2003;5:19-26 (Pubitemid 36506086)
51. Parati G. Continuous finger monitoring of blood pressure: advantages, problems and perspectives. Blood Press Monit 2000;5:47-49 (Pubitemid 30197915)
52. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl. 1):5-26 (Pubitemid 39349905)
53. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26(4):1176-1180 (Pubitemid 36929268)
54. McEwan P, Poole CD, Tetlow T, et al. Evaluation of the costeffectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl. 1):S7-S19
55. McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl. 1):S21-S31
56. National Institute for Clinical Excellence. The guidelines manual. Appendix H: Methodology checklist: economic evaluations. Available at: http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/ clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp [Last accessed 1st July 2009]
57. Warren E, Weatherly Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8(45) (Pubitemid 40125286)
58. NICE Guidance, Diabetes - insulin pump therapy. Available at: http://www.nice.org.uk/Guidance/TA151 [Last accessed 19 March 2009]
59. Henriksen OM, Røder ME, Prahl JB, et al. Diabetic ketoacidosis in Denmark incidence and mortality estimated from public health registries. Diabetes Res Clin Pract 2007;76:51-56